Bulletin du Cancer
MENUA phase II trial of miltefosine in patients with cutaneous T-cell lymphoma Volume 93, numéro 11, Novembre 2006
Illustrations
Service d’Hématologie, CH Lyon-Sud, Pierre-Bénite, Laboratoire d’Hématologie, Pavillon E, Hôpital Edouard-Herriot, 5 place d’Arsonval, 69003 Lyon Cedex 03, France, Service de Dermatologie, Hôtel-Dieu, Lyon, France, Baxter Oncologie, France
- Mots-clés : miltefosine, cutaneous T-cell lymphoma
- DOI : 10.1684/bdc.2006.0148
- Page(s) : 10115-8
- Année de parution : 2006
A phase II trial evaluating 6% topical miltefosine solution was performed in 12 pretreated patients with cutaneous T-cell lymphoma. Miltefosine (Miltex ®) was administered for 8 weeks, once per day during the first week then twice every day for seven weeks. Main side effects consisted in moderate to mild pruritus or desquamation in 57 % and 50 % of patients, respectively. No systemic nor biological toxicity was observed. This treatment was administered on an outpatient basis exclusively. The overall response rate was 58 % with a median duration of response of 12 months. Miltefosine is a safe, simple and effective treatment in certain patients with cutaneous T-cell lymphoma.